Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Daniel Kaufman
University of California Los Angeles, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
DIAMYD THERAPEUTICS AB
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
PI and is on the SAB for the company.
Repurposing lesogaberan for the treatment of type 1 diabetes
Relevance to Public Health We anticipate that our studies will provide a proof-of-principle that lesogaberan can be repurposed for treating T1D, potentially leading to rapid translation into clinical trials with T1D patients.
Filed on September 13, 2016.
Tell us what you know about Daniel Kaufman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Daniel Kaufman filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Daniel Kaufman | University of California Los Angeles | Conflict of Interest | DIAMYD THERAPEUTICS AB | $10,000 - $19,999 |
| Daniel Kaufman | University of California Los Angeles | Conflict of Interest | DIAMYD THERAPEUTICS AB | Value cannot be readily determined |
| Daniel Kaufman | University of California Los Angeles | Conflict of Interest | DIAMYD THERAPEUTICS AB | Value cannot be readily determined |
Other search results for: “Daniel Kaufman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Daniel Kaufman | University of California Los Angeles | Financial Disclosure | Diamyd Medical AB |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.